Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PORT WINE STAIN Clear all
Withdrawn Phase 2 Interventional

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

NCT01408056
View directory record Official record
Conditions
Infantile Hemangiomas
Interventions
Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 8 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

NCT01775722
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Pulsed Dye Laser, Combined Bipolar Radiofrequency&Pulsed Dye Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Not listed Early Phase 1 Interventional

Topical Simvastatin for Treating Infantile Hemangioma

NCT06273111
View directory record Official record
Conditions
Hemangioma Skin
Interventions
5% simvastatin ointment
Drug
Lead sponsor
Joyce Teng
Other
Eligibility
3 Months to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

NCT00800722
View directory record Official record
Conditions
Port Wine Stain
Interventions
Rapamycin Treatment of Port Wine Stain
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Measurement Skin Temperature During Pulsed Laser Exposure

NCT00540917
View directory record Official record
Conditions
Port-Wine Stain
Interventions
cooling spray during laser treatment
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
7 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Optical Tomographic Imaging of Infantile Hemangiomas

NCT01673971
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 7, 2026, 2:38 PM EDT
Withdrawn No phase listed Observational

Optical Frequency Domain Imaging (OFDI) in Dermatology

NCT01438047
View directory record Official record
Conditions
Port Wine Stain
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

NCT01056341
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Pierre Fabre Dermatology
Industry
Eligibility
35 Days to 150 Days
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Irvine, California • Redwood City, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

NCT02145884
View directory record Official record
Conditions
Hemangioma
Interventions
timolol maleate 0.5% gel
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
7 Days to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hemangioma Growth During the First 6 Months of Life

NCT00911781
View directory record Official record
Conditions
Hemangiomas of Infancy
Interventions
No intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 5 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Novel Treatment for Port Wine Stain Birthmarks

NCT01924273
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Talaporfin sodium
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

Tolerability of 532 nm Laser Treatment of Port Wine Stains

NCT05841628
View directory record Official record
Conditions
Port-Wine Stain
Interventions
532 nm laser treatment
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784
View directory record Official record
Conditions
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions
Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences

NCT00540371
View directory record Official record
Conditions
Port Wine Stain
Interventions
Port wine stain Birthmark
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Month to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Port Wine Stains Treatment Matrix RF Study

NCT01101360
View directory record Official record
Conditions
Port Wine Stains
Interventions
Matrix RF, Matrix RF followed by Pulse Dye Laser, Pulse Dye Laser followed by Matrix RF
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field Functional Imaging Technologies

NCT01333553
View directory record Official record
Conditions
PORT WINE STAIN
Interventions
Image-guided remove Port Wine Stain
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Day and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 7, 2026, 2:38 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Pilot Study to Evaluate the Effect of Multiple Passes on Port Wine Stain Treatments With the Cutera Excel V™ Laser.

NCT04103164
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Cutera excel V™ Laser
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Early Phase 1 Interventional

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

NCT01015300
View directory record Official record
Conditions
Hemangioblastomas, Von Hippel Lindau Disease
Interventions
Avastin
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational Results available

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

NCT03652181
View directory record Official record
Conditions
CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1, Cerebral Cavernous Malformations 2, Cerebral Cavernous Malformations 3, Cavernous Angioma
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

NCT00052013
View directory record Official record
Conditions
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 7, 2026, 2:38 PM EDT